VHL 抗体
(Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008].
| Catalog no. | 产品 | 适用 | 宿主 / 克隆类型 | 应用 | 价格和交货时间 |
|---|---|---|---|---|---|
| VHL 抗体 (AA 101-200) (AbBy Fluor® 488) | 人 | 兔 Polyclonal |
|
|
|
| VHL 抗体 (AA 101-200) (AbBy Fluor® 647) | 人 | 兔 Polyclonal |
|
|
|
| VHL 抗体 (AA 101-200) (Cy5) | 人 | 兔 Polyclonal |
|
|
|
| VHL 抗体 (AA 101-200) (AbBy Fluor® 555) | 人 | 兔 Polyclonal |
|
|
|
| VHL 抗体 (AA 101-200) (AbBy Fluor® 680) | 人 | 兔 Polyclonal |
|
|
|
| VHL 抗体 (AA 101-200) (Cy3) | 人 | 兔 Polyclonal |
|
|
|
| VHL 抗体 (AA 101-200) (FITC) | 人 | 兔 Polyclonal |
|
|
|
| VHL 抗体 (AA 101-200) (HRP) | 人 | 兔 Polyclonal |
|
|
|
| VHL 抗体 (AA 70-213) | 人 | 兔 Polyclonal |
|
|
|
| VHL 抗体 (pSer68) | 人, 大鼠, 小鼠 | 兔 Polyclonal |
|
|
|
| VHL 抗体 | 人, 大鼠, 小鼠 | 兔 Polyclonal |
|
|
|
| VHL 抗体 (AA 1-50) | 人, 大鼠, 小鼠 | 兔 Polyclonal |
|
|
|
| VHL 抗体 (AA 43-71) | 人 | 兔 Polyclonal |
|
|
|
| VHL 抗体 (AA 1-54, AA 1-213) | 人, 小鼠 | 小鼠 Monoclonal |
|
|
|
| VHL 抗体 (pSer68) | 人 | 兔 Polyclonal |
|
|
|
| VHL 抗体 (AA 1-154) | 人 | 小鼠 Monoclonal |
|
|
|
| VHL 抗体 (Tyr309) | 人, 大鼠, 小鼠 | 兔 Polyclonal |
|
|
|
| VHL 抗体 (pSer68) | 人, 大鼠, 小鼠 | 兔 Polyclonal |
|
|
|
| VHL 抗体 | 大鼠 | 小鼠 Monoclonal |
|
|
|
| VHL 抗体 (AA 34-83) | 人, 大鼠, 小鼠 | 兔 Polyclonal |
|
|
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 488
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 647
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- Cy5
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 555
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 680
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- Cy3
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- FITC
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 所列应用)
- IHC (fro) (Immunohistochemistry (Frozen Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- HRP
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 70-213
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- ELISA (ELISA: 所列应用)
- IF (Immunofluorescence: 所列应用)
- 适用
- 人, 大鼠, 小鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- pSer68
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- ELISA (ELISA: 所列应用)
- IF (Immunofluorescence: 所列应用)
- 适用
- 人, 大鼠, 小鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 1-50
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 43-71
Primary Antibody
- ELISA (ELISA: 所列应用)
- 适用
- 人, 小鼠
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 标记
- unconjugated
- 抗体亚型
- IgG1 kappa
- 抗原表位
- AA 1-213, AA 1-54
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- pSer68
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- IF (Immunofluorescence: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- AT82B10
- 标记
- unconjugated
- 抗体亚型
- IgG2b kappa
- 抗原表位
- AA 1-154
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- ELISA (ELISA: 所列应用)
- 适用
- 人, 大鼠, 小鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- Tyr309
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- ELISA (ELISA: 所列应用)
- 适用
- 人, 大鼠, 小鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- pSer68
Primary Antibody
- IHC (Immunohistochemistry: 有验证图片)
- ELISA (ELISA: 所列应用)
- IF (Immunofluorescence: 所列应用)
- 适用
- 人, 大鼠, 小鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 34-83
Latest Publications for our VHL 抗体
: "Protective effect of salidroside against bone loss via hypoxia-inducible factor-1α pathway-induced angiogenesis." in: Scientific reports, Vol. 6, pp. 32131, (2018) (PubMed).
: "VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2." in: Nature communications, Vol. 8, pp. 15337, (2018) (PubMed).
: "Salidroside accelerates fracture healing through cell-autonomous and non-autonomous effects on osteoblasts." in: Cell and tissue research, Vol. 367, Issue 2, pp. 197-211, (2017) (PubMed).
: "Forkhead Transcription Factor 3a (FOXO3a) Modulates Hypoxia Signaling via Up-regulation of the von Hippel-Lindau Gene (VHL)." in: The Journal of biological chemistry, Vol. 291, Issue 49, pp. 25692-25705, (2017) (PubMed).
: "An ID2-dependent mechanism for VHL inactivation in cancer." in: Nature, Vol. 529, Issue 7585, pp. 172-7, (2016) (PubMed).
: "Jumonji Domain Containing Protein 6: A Novel Oxygen Sensor in the Human Placenta." in: Endocrinology, Vol. 156, Issue 8, pp. 3012-25, (2015) (PubMed).
: "HIF-1α disturbs osteoblasts and osteoclasts coupling in bone remodeling by up-regulating OPG expression." in: In vitro cellular & developmental biology. Animal, Vol. 51, Issue 8, pp. 808-14, (2015) (PubMed).
: "pVHL Negatively Regulates Antiviral Signaling by Targeting MAVS for Proteasomal Degradation." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 195, Issue 4, pp. 1782-90, (2015) (PubMed).
: "The von hippel-lindau protein suppresses androgen receptor activity." in: Molecular endocrinology (Baltimore, Md.), Vol. 28, Issue 2, pp. 239-48, (2015) (PubMed).
: "Hypoxia inducible factor-1α suppresses Peroxiredoxin 3 expression to promote proliferation of CCRCC cells." in: FEBS letters, Vol. 588, Issue 18, pp. 3390-4, (2014) (PubMed).
: "VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2." in: Nature communications, Vol. 8, pp. 15337, (2018) (PubMed).
: "Salidroside accelerates fracture healing through cell-autonomous and non-autonomous effects on osteoblasts." in: Cell and tissue research, Vol. 367, Issue 2, pp. 197-211, (2017) (PubMed).
: "Forkhead Transcription Factor 3a (FOXO3a) Modulates Hypoxia Signaling via Up-regulation of the von Hippel-Lindau Gene (VHL)." in: The Journal of biological chemistry, Vol. 291, Issue 49, pp. 25692-25705, (2017) (PubMed).
: "An ID2-dependent mechanism for VHL inactivation in cancer." in: Nature, Vol. 529, Issue 7585, pp. 172-7, (2016) (PubMed).
: "Jumonji Domain Containing Protein 6: A Novel Oxygen Sensor in the Human Placenta." in: Endocrinology, Vol. 156, Issue 8, pp. 3012-25, (2015) (PubMed).
: "HIF-1α disturbs osteoblasts and osteoclasts coupling in bone remodeling by up-regulating OPG expression." in: In vitro cellular & developmental biology. Animal, Vol. 51, Issue 8, pp. 808-14, (2015) (PubMed).
: "pVHL Negatively Regulates Antiviral Signaling by Targeting MAVS for Proteasomal Degradation." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 195, Issue 4, pp. 1782-90, (2015) (PubMed).
: "The von hippel-lindau protein suppresses androgen receptor activity." in: Molecular endocrinology (Baltimore, Md.), Vol. 28, Issue 2, pp. 239-48, (2015) (PubMed).
: "Hypoxia inducible factor-1α suppresses Peroxiredoxin 3 expression to promote proliferation of CCRCC cells." in: FEBS letters, Vol. 588, Issue 18, pp. 3390-4, (2014) (PubMed).
Aliases for VHL 抗体
von Hippel-Lindau tumor suppressor (VHL) 抗体von Hippel-Lindau (Vhl) 抗体
von Hippel-Lindau tumor suppressor (vhl) 抗体
von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase (VHL) 抗体
von Hippel-Lindau disease tumor suppressor (CpipJ_CPIJ009992) 抗体
von Hippel-Lindau tumor suppressor (Vhl) 抗体
BcDNA:RH61560 抗体
CG13221 抗体
d-VHL 抗体
d-vhl 抗体
Dmel\\CG13221 抗体
dmVHL 抗体
DVhl 抗体
Dvhl 抗体
dVHL 抗体
HRCA1 抗体
hrca1 抗体
pVHL 抗体
RCA1 抗体
rca1 抗体
VHL 抗体
vhl 抗体
VHL1 抗体
vhl1 抗体
Vhlh 抗体
zgc:158722 抗体
您还需要查找其他产品吗？
- VGLL4 抗体
- VGLL3 抗体
- VGLL1 抗体
- VGF 抗体
- VEZT 抗体
- VEZF1 抗体
- Vestigial Like 2 抗体
- Vestigial 抗体
- Vesicle-Associated Membrane Protein 1 (Synaptobrevin 1) 抗体
- Vesicle Transport Protein SFT2B 抗体
- Very Low Density Lipoprotein 抗体
- VENTX 抗体
- Ventral Anterior Homeobox 1 抗体
- VEGFR2/CD309 抗体
- VEGFD 抗体
- VEGFC 抗体
- VEGFB 抗体
- VEGF121 抗体
- VEGF 抗体
- VDAC3 抗体
You are here:
